SCHEMBL30749004

SCHEMBL30749004

C[C@@H]1CN(c2ncc(N3C(=O)C4(CCCC4)c4c(NC5CCC5)nc(CO)nc43)cn2)C[C@H](C)O1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.33
HSD11B1 P28845 1/20 0.32
NR2F2 P24468 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
S1PR2 O95136 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
XBP1 P17861 1/20 0.32
RAB9A P51151 1/20 0.32
PPP1CA P62136 1/20 0.32
KMT2A Q03164 1/20 0.32
ALOX15 P16050 1/20 0.32
AOC3 Q16853 1/20 0.32
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748929 0.91 ALOX15 (0.33) HDAC6HSD11B1ALOX15AOC3CDK4
SCHEMBL31691334 0.90 HDAC6 (0.34) HDAC6HSD11B1NR2F2NPSR1KDM4E
SCHEMBL31691221 0.87
SCHEMBL31627040 0.86 CHRM4 (0.32) HDAC6ALOX15AOC3
SCHEMBL30749129 0.86 AOC3 (0.36) HDAC6HSD11B1MAPTMAPK1ALDH1A1
SCHEMBL31691422 0.85 CHRM3 (0.37) NR2F2NPSR1KDM4EMAPTMAPK1
SCHEMBL31691216 0.82 DDR1 (0.31)
SCHEMBL30748916 0.79 HDAC6 (0.34) HDAC6HSD11B1MAPTRAB9AALOX15
SCHEMBL31691380 0.78 ALOX15 (0.30) ALOX15
SCHEMBL31691224 0.77 NR2F2 (0.30) NR2F2NPSR1KDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT HDAC6 931/4885HSD11B1 495/4885NR2F2 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.